Innate Resistance and Susceptibility to Norovirus Infection

PLoS Pathogens

Volumn 12, Issue 4, 2016, Pages

  Nordgren, Johan ^a   Sharma, Sumit ^a   Kambhampati, Anita ^b   Lopman, Ben ^b   Svensson, Lennart ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD GROUP ANTIGEN; FUCOSYLTRANSFERASE; VIRULENCE FACTOR;

DISEASE PREDISPOSITION; DNA POLYMORPHISM; ETHNICITY; GASTROENTERITIS; GENOTYPE; HEREDITY; HUMAN; IMMUNIZATION; INNATE IMMUNITY; NONHUMAN; NONSENSE MUTATION; NOROVIRUS INFECTION; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; ANIMAL; CALICIVIRUS INFECTION; GENETIC PREDISPOSITION; GENETICS; VIROLOGY;

ANIMALS; CALICIVIRIDAE INFECTIONS; GASTROENTERITIS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS;

EID: 84964723596     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1005385     Document Type: Review

References (33)

1. Rydell GE, Kindberg E, Larson G, Svensson L, Susceptibility to winter vomiting disease: a sweet matter. Reviews in medical virology. 2011;21(6):370–82. doi: 10.1002/rmv.70422025362.
2. Ahmed SM, Hall AJ, Robinson AE, Verhoef L, Premkumar P, Parashar UD, et al. Global prevalence of norovirus in cases of gastroenteritis: a systematic review and meta-analysis. The Lancet Infectious diseases. 2014;14(8):725–30. doi: 10.1016/S1473-3099(14)70767-424981041.
3. Bucardo F, Kindberg E, Paniagua M, Grahn A, Larson G, Vildevall M, et al. Genetic susceptibility to symptomatic norovirus infection in Nicaragua. J Med Virol. 2009;81(4):728–35. doi: 10.1002/jmv.2142619235844.
4. Castanys-Munoz E, Martin MJ, Prieto PA, 2'-fucosyllactose: an abundant, genetically determined soluble glycan present in human milk. Nutr Rev. 2013;71(12):773–89. doi: 10.1111/nure.1207924246032.
5. Le Pendu J, Ruvoen-Clouet N, Kindberg E, Svensson L, Mendelian resistance to human norovirus infections. Seminars in immunology. 2006;18(6):375–86. doi: 10.1016/j.smim.2006.07.00916973373.
6. Jones MK, Watanabe M, Zhu S, Graves CL, Keyes LR, Grau KR, et al. Enteric bacteria promote human and mouse norovirus infection of B cells. Science. 2014;346(6210):755–9. doi: 10.1126/science.125714725378626; PubMed Central PMCID: PMC4401463.
7. Wacklin P, Tuimala J, Nikkila J, Sebastian T, Makivuokko H, Alakulppi N, et al. Faecal microbiota composition in adults is associated with the FUT2 gene determining the secretor status. PLoS ONE. 2014;9(4):e94863. doi: 10.1371/journal.pone.009486324733310; PubMed Central PMCID: PMC3986271.
8. Meng D, Newburg DS, Young C, Baker A, Tonkonogy SL, Sartor RB, et al. Bacterial symbionts induce a FUT2-dependent fucosylated niche on colonic epithelium via ERK and JNK signaling. Am J Physiol Gastrointest Liver Physiol. 2007;293(4):G780–7. doi: 10.1152/ajpgi.00010.200717673542.
9. Miura T, Sano D, Suenaga A, Yoshimura T, Fuzawa M, Nakagomi T, et al. Histo-blood group antigen-like substances of human enteric bacteria as specific adsorbents for human noroviruses. J Virol. 2013;87(17):9441–51. doi: 10.1128/JVI.01060-1323804639; PubMed Central PMCID: PMC3754087.
10. Parrino TA, Schreiber DS, Trier JS, Kapikian AZ, Blacklow NR, Clinical immunity in acute gastroenteritis caused by Norwalk agent. The New England journal of medicine. 1977;297(2):86–9. doi: 10.1056/NEJM197707142970204405590.
11. Huhti L, Szakal ED, Puustinen L, Salminen M, Huhtala H, Valve O, et al. Norovirus GII-4 causes a more severe gastroenteritis than other noroviruses in young children. The Journal of infectious diseases. 2011;203(10):1442–4. doi: 10.1093/infdis/jir03921415019; PubMed Central PMCID: PMC3080904.
12. Bucardo F, Nordgren J, Carlsson B, Paniagua M, Lindgren PE, Espinoza F, et al. Pediatric norovirus diarrhea in Nicaragua. J Clin Microbiol. 2008;46(8):2573–80. doi: 10.1128/JCM.00505-0818562593; PubMed Central PMCID: PMC2519475.
13. Currier RL, Payne DC, Staat MA, Selvarangan R, Shirley SH, Halasa N, et al. Innate susceptibility to norovirus infections influenced by FUT2 genotype in a United States pediatric population. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2015. doi: 10.1093/cid/civ16525744498.
14. Liu P, Wang X, Lee JC, Teunis P, Hu S, Paradise HT, et al. Genetic susceptibility to norovirus GII.3 and GII.4 infections in Chinese pediatric diarrheal disease. The Pediatric infectious disease journal. 2014;33(11):e305–9. doi: 10.1097/INF.000000000000044325037042.
15. Lopman BA, Trivedi T, Vicuna Y, Costantini V, Collins N, Gregoricus N, et al. Norovirus Infection and Disease in an Ecuadorian Birth Cohort: Association of Certain Norovirus Genotypes With Host FUT2 Secretor Status. J Infect Dis. 2014. doi: 10.1093/infdis/jiu67225505295.
16. Nordgren J, Nitiema LW, Ouermi D, Simpore J, Svensson L, Host genetic factors affect susceptibility to norovirus infections in Burkina Faso. PLoS ONE. 2013;8(7):e69557. doi: 10.1371/journal.pone.006955723894502; PubMed Central PMCID: PMC3716642.
17. de Rougemont A, Ruvoen-Clouet N, Simon B, Estienney M, Elie-Caille C, Aho S, et al. Qualitative and quantitative analysis of the binding of GII.4 norovirus variants onto human blood group antigens. J Virol. 2011;85(9):4057–70. doi: 10.1128/JVI.02077-1021345963; PubMed Central PMCID: PMC3126233.
18. Carlsson B, Kindberg E, Buesa J, Rydell GE, Lidon MF, Montava R, et al. The G428A nonsense mutation in FUT2 provides strong but not absolute protection against symptomatic GII.4 Norovirus infection. PLoS ONE. 2009;4(5):e5593. doi: 10.1371/journal.pone.000559319440360; PubMed Central PMCID: PMC2680586.
19. Frenck R, Bernstein DI, Xia M, Huang P, Zhong W, Parker S, et al. Predicting susceptibility to norovirus GII.4 by use of a challenge model involving humans. J Infect Dis. 2012;206(9):1386–93. doi: 10.1093/infdis/jis51422927452.
20. Jin M, He Y, Li H, Huang P, Zhong W, Yang H, et al. Two gastroenteritis outbreaks caused by GII Noroviruses: host susceptibility and HBGA phenotypes. PLoS ONE. 2013;8(3):e58605. doi: 10.1371/journal.pone.005860523472212; PubMed Central PMCID: PMC3589376.
21. Lindesmith L, Moe C, Lependu J, Frelinger JA, Treanor J, Baric RS, Cellular and humoral immunity following Snow Mountain virus challenge. J Virol. 2005;79(5):2900–9. doi: 10.1128/JVI.79.5.2900-2909.200515709009; PubMed Central PMCID: PMC548455.
22. Nordgren J, Kindberg E, Lindgren PE, Matussek A, Svensson L, Norovirus gastroenteritis outbreak with a secretor-independent susceptibility pattern, Sweden. Emerging infectious diseases. 2010;16(1):81–7. doi: 10.3201/eid1601.09063320031047; PubMed Central PMCID: PMC2874438.
23. Rockx BH, Vennema H, Hoebe CJ, Duizer E, Koopmans MP, Association of histo-blood group antigens and susceptibility to norovirus infections. J Infect Dis. 2005;191(5):749–54. doi: 10.1086/42777915688291.
24. Bucardo F, Reyes Y, Svensson L, Nordgren J, Predominance of norovirus and sapovirus in Nicaragua after implementation of universal rotavirus vaccination. PLoS ONE. 2014;9(5):e98201. doi: 10.1371/journal.pone.009820124849288; PubMed Central PMCID: PMC4029982.
25. Gomez-Santiago F, Ribas-Aparicio RM, Garcia-Lozano H, Molecular characterization of human calicivirus associated with acute diarrheal disease in Mexican children. Virol J. 2012;9:54. doi: 10.1186/1743-422X-9-5422361160; PubMed Central PMCID: PMC3337238.
26. Chang JG, Yang TY, Liu TC, Lin TP, Hu CJ, Kao MC, et al. Molecular analysis of secretor type alpha(1,2)-fucosyltransferase gene mutations in the Chinese and Thai populations. Transfusion. 1999;39(9):1013–7. 10533829.
27. Atmar RL, Bernstein DI, Harro CD, Al-Ibrahim MS, Chen WH, Ferreira J, et al. Norovirus vaccine against experimental human Norwalk Virus illness. The New England journal of medicine. 2011;365(23):2178–87. doi: 10.1056/NEJMoa110124522150036; PubMed Central PMCID: PMC3761795.
28. Bernstein DI, Atmar RL, Lyon GM, Treanor JJ, Chen WH, Jiang X, et al. Norovirus vaccine against experimental human GII.4 virus illness: a challenge study in healthy adults. J Infect Dis. 2015;211(6):870–8. doi: 10.1093/infdis/jiu49725210140.
29. LoBue AD, Lindesmith L, Yount B, Harrington PR, Thompson JM, Johnston RE, et al. Multivalent norovirus vaccines induce strong mucosal and systemic blocking antibodies against multiple strains. Vaccine. 2006;24(24):5220–34. doi: 10.1016/j.vaccine.2006.03.08016650512.
30. Rockx B, Baric RS, de Grijs I, Duizer E, Koopmans MP, Characterization of the homo- and heterotypic immune responses after natural norovirus infection. J Med Virol. 2005;77(3):439–46. doi: 10.1002/jmv.2047316173019.
31. Lindesmith LC, Ferris MT, Mullan CW, Ferreira J, Debbink K, Swanstrom J, et al. Broad blockade antibody responses in human volunteers after immunization with a multivalent norovirus VLP candidate vaccine: immunological analyses from a phase I clinical trial. PLoS Med. 2015;12(3):e1001807. doi: 10.1371/journal.pmed.100180725803642; PubMed Central PMCID: PMC4371888.
32. Treanor JJ, Atmar RL, Frey SE, Gormley R, Chen WH, Ferreira J, et al. A novel intramuscular bivalent norovirus virus-like particle vaccine candidate—reactogenicity, safety, and immunogenicity in a phase 1 trial in healthy adults. J Infect Dis. 2014;210(11):1763–71. doi: 10.1093/infdis/jiu33724951828.
33. Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, Lynfield R, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet. 2006;368(9546):1495–502. doi: 10.1016/S0140-6736(06)69637-217071283.